109 citations
,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
Men over 50 often experience urinary issues due to prostate enlargement or bladder problems, treatable with therapies, medications, or surgery.
4 citations
,
February 2016 in “The Journal of urology/The journal of urology” Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
January 2014 in “Hebei yixue” Combining tamsulosin and finasteride effectively improves urinary symptoms in elderly BPH patients.
1 citations
,
November 2021 in “Société internationale d'urologie journal” Doctors should adjust how they treat men with prostate-related urinary problems during and after the COVID-19 pandemic.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
33 citations
,
July 2009 in “Therapeutics and Clinical Risk Management” Finasteride effectively reduces prostate size and lowers surgery risk in men with benign prostatic hyperplasia.
January 2026 in “Journal of Pharmacy & Bioresources” Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.
March 2017 in “Journal of endourology” The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.
January 2011 in “China Modern Doctor” Combining longxuejie and finasteride effectively reduces bleeding during TURP without side effects.
January 2005 in “Urology” Alfuzosin reduces short-term surgery need after catheter removal, but long-term benefits are unclear; combination therapy may help prevent urinary issues.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
1 citations
,
October 2006 in “Urology” Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.
January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.
5 citations
,
December 2024 in “Archivio Italiano di Urologia e Andrologia” Personalized treatment is crucial for effectively managing benign prostatic hyperplasia (BPH).
January 2023 in “Springer eBooks” 14 citations
,
January 2020 in “Archivio Italiano di Urologia e Andrologia” Finasteride helps with prostate symptoms but may cause sexual side effects.
March 2018 in “European Urology Supplements” Patients follow treatment well, but many change medicines; good information helps compliance.
2 citations
,
November 2023 in “International Journal of Preventive Medicine and Health (IJPMH)” The Unani Pharmacopoeia-Based Formulation significantly improved symptoms of enlarged prostate in rats.
1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
November 2024 in “Singapore Medical Journal” A bladder rupture from prostate treatment was healed with catheterization and antibiotics.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
19 citations
,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
30 citations
,
July 2001 in “BJUI” Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.